Planned Downtime - beginning Feb 10, 6PM PST until Feb 11, 6AM PST
On February 10th at 6PM PST, we're performing system upgrades at DeepDyve. We'll be down for 12 hours, during which time our site will be unavailable. Thanks for your patience and support.
Sorry, the document you expected is no longer available. Below are search results for the title of the document.
for: immune based therapy for chronic hepatitis c
- All Journals
- Clinical Chemistry And Laboratory Medicine (45)
- Clinical Immunology (35)
- Digestive Diseases And Sciences (32)
- Journal Of Gastroenterology (20)
- The American Journal Of Medicine (20)
- Journal Of Leukocyte Biology (17)
- Annual Review Of Medicine (16)
- Pediatric Nephrology (16)
- Biochemical And Biophysical Research Communications (15)
- Intensive Care Medicine (15)
- Transplantation Proceedings (14)
- Clinical Therapeutics (13)
- Current Opinion In Immunology (12)
- Journal Of Gene Medicine (12)
- Advanced Drug Delivery Reviews (10)
- More...
- All Subject Areas
- Medicine (510)
- Life Sciences (164)
- Life Sciences And Medical (135)
- Physics And Physical Sciences (13)
- Social Sciences (12)
- Business And Finance (2)
- Humanities (1)
- Humanities And Social Sciences (1)
- More...
- All Articles
- Rentable (747)
- Free (0)
- Restricted (0)
-
Bookmark
More Like This 0p9zu5OSqZ $2.99
Immune-based therapy for chronic hepatitis C
Chang, Dong-Yeop; Shin, Eui-Cheol
Follow Journal of Leukocyte Biology , Volume 86 (1): 33
Fed of American Socs for Experimental Biology – Jul 1, 2009strategies typically involve boosting the immune responses against HCV. These immune-based therapies for chronic HCV infection include therapeutic vaccines, antagonists of T cell inhibitory factors, anti-HCV ...
-
Bookmark
More Like This Y3X7tFviLm $0.99
Interferon-based therapy of hepatitis C
Chevaliez, Stéphane; Pawlotsky, Jean-Michel
Follow Advanced Drug Delivery Reviews , Volume 59 (12)
Elsevier – Oct 10, 2007In 2007, the world celebrated the 50th anniversary of the discovery of interferon (IFN). The first clinical trial of recombinant IFN–α in patients with chronic hepatitis C was published in 1986 ...
-
Bookmark
More Like This J8EJLQYPgd $4.99
The Management of Chronic Hepatitis B in Asian Americans
Myron, Tong; Calvin, Pan; Hie-Won, Hann; Kris, Kowdley; Steven-Huy, Han; Albert, Min; Truong-Sinh, Leduc
Follow Digestive Diseases and Sciences , Volume 56 (11)
Springer Journals – Nov 1, 2011for liver complications should be identified and offered antiviral therapy. The two antiviral agents recommended for first-line treatment of chronic hepatitis B (CHB) are entecavir and tenofovir. The primary ...
-
Bookmark
More Like This ad5BtCXDAs $4.99
Prevalence of rheumatologic manifestations of chronic hepatitis C virus infection among Egyptians
Reem, Mohammed; Hesham, ElMakhzangy; Amira, Gamal; Fatma, Mekky; Mohammed, Kassas; Nabil, Mohammed; Mohammed, Hamid; Gamal, Esmat
Follow Clinical Rheumatology , Volume 29 (12)
Springer Journals – Dec 1, 2010of inflammatory arthritis [22]. Plain chest radiographs was done in patients with rheumatic manifestations to screen for idiopathic lung fibrosis. The diagnosis of chronic hepatitis C was based on the presence ...
-
Bookmark
More Like This jlTeXyBzDQ $3.99
Chronic hepatitis C virus infection and increases in viral load in a prospective cohort of young, HIV-uninfected injection drug users
Boodram, Basmattee; Hershow, Ronald C.; Cotler, Scott J.; Ouellet, Lawrence J.
Follow Drug and Alcohol Dependence , Volume 119 (3)
Elsevier – Dec 15, 2011Background Chronic hepatitis C (HCV) infection, defined as persistent RNA (viral load) for at least 6 months, accounts for up to 50% of all cirrhosis, end-stage liver disease and liver cancer cases ...
-
Bookmark
More Like This Dcd6BhLORJ $4.99
Very Low Viral Load (VLVL) Relapse Following Treatment of Naïve Patients with Chronic Hepatitis C
John, Hoefs; Vikramjit, Aulakh; Bernard, Ilagan
Follow Digestive Diseases and Sciences , Volume 57 (1)
Springer Journals – Jan 1, 2012with chronic hepatitis C (HCV) with pegylated interferon and ribavirin is 50â60%. Patients who relapse have a poor response to re-treatment. We report a group of relapse patients with SVR to low-dose re ...
-
Bookmark
More Like This 0gtrb2c5jm $0.99
Immune responses during acute and chronic infection with hepatitis C virus
Ishii, Shigeaki; Koziel, Margaret James
Follow Clinical Immunology , Volume 128 (2)
Elsevier – Aug 1, 2008Hepatitis C virus (HCV) induces persistent infection and causes chronic liver disease in most infected patients. Vigorous HCV-specific CD4+ and CD8+ T cell responses against HCV multiple epitopes ...
-
Bookmark
More Like This wqyS7ZiAXw $3.99
Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus
Kauffman, Robert S; Hurter, Patricia; Mueller, Peter; Kwong, Ann D
Follow Nature Biotechnology , Volume 29 (11)
Nature Publishing Group (NPG) – Nov 8, 2011, major scientific advances have enabled the development of new classes of HCV therapy, the direct-acting antiviral agents, also known as specifically targeted antiviral therapy for hepatitis C (STAT-C ...
-
Bookmark
More Like This V65QRI1CoM $3.99
Passive immunization: the forgotten arm of immunologically based strategies for disease containment
Gonik, Bernard
Follow American Journal of Obstetrics and Gynecology , Volume 205 (5)
Elsevier – Nov 1, 2011A virus Until the recent availability of hepatitis A vaccines, immune globulin therapy was the mainstay of the prevention of the hepatitis A virus for people who either were likely to be exposed or had ...
-
Bookmark
More Like This N0SeN202Ye $0.99
Clinical experience with α-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection
Schneiders, Famke L.; Scheper, Rik J.; von Blomberg, B. Mary E.; Woltman, Andrea M.; Janssen, Harry L.A.; van den Eertwegh, Alfons J.M.; Verheul, Henk M.W.; de Gruijl, Tanja D.; van der Vliet, Hans J.
Follow Clinical Immunology , Volume 140 (2)
Elsevier – Aug 1, 2011. Here, we will provide a brief overview of the preclinical data of α-galactosylceramide that formed the basis for subsequent clinical trials in patients with advanced cancer and chronic hepatitis B/C ...
© 2012 DeepDyve, Inc. All rights reserved.
Terms of Service | Privacy Policy
